News

Press Releases

May 17, 2022
Exo Therapeutics Appoints Stephanos Ioannidis as Executive Vice President, Drug Discovery and Catherine Scholz as Senior Vice President, Program Management

April 26, 2022
Exo Therapeutics Appoints Laura Kiessling to Scientific Advisory Board

January 18, 2022
Exo Therapeutics Appoints Antonio Gualberto as President of Research & Development and Chief Medical Officer

October 26, 2021
Exo Therapeutics Appoints Dorothy Lou Bailey as Senior Vice President, Corporate Development and Strategy

October 5, 2021
Exo Therapeutics Raises $78 Million Series B Financing

March 30, 2021
Exo Therapeutics Appoints Nagesh Mahanthappa to Board of Directors and Charles W. Roberts to Scientific Advisory Board

December 16, 2020
Exo Therapeutics Launches with $25 Million Series A Financing to Unlock Intractable Drug Targets with Exosites

July 23, 2020
A startup emerging from David Liu’s lab intends to commercialize a small-molecule enzyme inhibitor discovery platform to generate more potent drugs with higher specificity.

We are a diverse group of scientists, researchers, and business leaders with the mission to develop a novel approach to medicines discovery with exosites.
Careers